API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.globenewswire.com/news-release/2024/04/11/2861365/0/en/Athira-Pharma-Announces-Publication-of-Preclinical-Data-Highlighting-Fosgonimeton-Treatment-in-Models-of-Alzheimer-s-Disease.html
https://www.globenewswire.com/news-release/2024/03/08/2843025/0/en/Athira-Pharma-Presents-Clinical-and-Preclinical-Data-Supporting-Therapeutic-Potential-of-Fosgonimeton-in-Alzheimer-s-and-Parkinson-s-Diseases-at-AD-PD-2024-International-Conference.html
https://www.globenewswire.com//news-release/2024/01/03/2803137/0/en/Athira-Pharma-Completes-Enrollment-of-Phase-2-3-LIFT-AD-Clinical-Trial-of-Fosgonimeton-in-Mild-to-Moderate-Alzheimer-s-Disease.html
https://www.globenewswire.com//news-release/2023/12/12/2794592/0/en/Athira-Pharma-Announces-Encouraging-Results-from-SHAPE-Phase-2-Clinical-Trial-of-Fosgonimeton-for-the-Treatment-of-Parkinson-s-Disease-Dementia-and-Dementia-with-Lewy-Bodies.html
https://www.fiercebiotech.com/biotech/athiras-losing-streak-continues-phase-2-failure-dementia
https://www.globenewswire.com/news-release/2022/09/06/2510202/0/en/Athira-Pharma-Provides-Update-on-Plans-for-Ongoing-LIFT-AD-Clinical-Study-of-Fosgonimeton-in-Mild-to-Moderate-Alzheimer-s-Patients.html
https://www.globenewswire.com/news-release/2022/08/15/2498550/0/en/Athira-Pharma-Reports-Second-Quarter-2022-Financial-Results-and-Recent-Clinical-and-Corporate-Updates.html